论文部分内容阅读
目的:观察白三烯受体拮抗剂顺尔宁用于治疗小儿哮喘的疗效。方法:收集2012年8月至2013年8月期间,我院收治的哮喘患儿86例,随机分为观察组与对照组,每组43例,对照组予以常规抗哮喘治疗,观察组在常规治疗的基础上加用白三烯受体拮抗剂顺尔宁进行治疗,对比分析两组的临床疗效。结果:观察组的治疗总有效率显著高于对照组,疗程症状消失时间显著短于对照组,复发率显著低于对照组(P<0.05);两组不良反应率无明显差异(P>0.05)。结论:白三烯受体拮抗剂顺尔宁用于治疗小儿哮喘疗效显著、安全可靠、不良反应少,值得在临床中应用。
OBJECTIVE: To observe the effect of leukotriene receptor antagonist Shundening on the treatment of pediatric asthma. Methods: From August 2012 to August 2013, 86 children with asthma admitted to our hospital were randomly divided into observation group and control group, with 43 cases in each group. The control group was given conventional anti-asthma treatment, Treatment based on the addition of leukotriene receptor antagonist Sulfantion treatment, comparative analysis of the clinical efficacy of the two groups. Results: The total effective rate in the observation group was significantly higher than that in the control group. The duration of disappearance of symptoms was significantly shorter in the observation group than in the control group, and the recurrence rate was significantly lower than that in the control group (P <0.05). There was no significant difference in adverse reactions between the two groups ). Conclusion: The effect of leukotriene receptor antagonist Shundening on asthma in children is significant, safe and reliable with few adverse reactions, which is worthy of clinical application.